The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation—A Monocentric Cross-Sectional Pilot Study [PDF]
Medicina, 2022 Background and Objectives: The present study aims to analyze the complex patient/treating physician interaction at onset of botulinum toxin (BoNT) therapy in patients with idiopathic cervical dystonia (CD) and the influence of high initial doses on long ...
Harald Hefter +4 more
doaj +2 more sources
Lentiviral gene therapy prevents anti-human acid α-glucosidase antibody formation in murine Pompe disease [PDF]
Molecular Therapy: Methods & Clinical Development, 2022 Enzyme replacement therapy (ERT) is the current standard treatment for Pompe disease, a lysosomal storage disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA).
Qiushi Liang +10 more
doaj +2 more sources
Prevalence and clinical implications of anti-drug antibody formation and serum drug levels among patients with IBD receiving anti-TNF therapy: A cross-sectional study [PDF]
The Saudi Journal of GastroenterologyBackground: The emergence of tumor necrosis factor inhibitors (anti-TNF) has considerably changed the management of inflammatory bowel disease (IBD) in patients who do not respond to traditional therapies.
Ahmed Alghamdi +12 more
doaj +2 more sources
Journal of Experimental Medicine, 1961 The suppression of antibody formation by passively administered antibody is influenced by the dose and nature of the antigen, type of immunization procedure, ratio of antibody to antigen, species origin and characteristics of the antiserum used, as well as the species selected for immunization.
Jonathan W Uhr, Uhr Jonathan W
exaly +3 more sources
ANTIBODY FORMATION IN VITRO [PDF]
Journal of Experimental Medicine, 1961 Neutralizing activity against T2 bacteriophage appeared in cultures of lymph node cells from normal rats in response to their in vitro stimulation with a cell-free filtrate derived from homogenized rat macrophages which had been incubated with T2 bacteriophage. This activity was specifically directed against T2 bacteriophage.
exaly +3 more sources
Journal of Experimental Medicine, 1962 Injection of a small bacteriophage ϕX 174 into guinea pigs results in an accelerated elimination of phage detectable as early as 24 hours after injection. The immune nature of the accelerated elimination is indicated by its specificity, by the appearance of excess specific serum antibody after phage elimination, and by the prevention of accelerated ...
Jonathan W Uhr +2 more
exaly +2 more sources
Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation [PDF]
Frontiers in Immunology, 2020 Anti-factor VIII (fVIII) alloantibodies, which can develop in patients with hemophilia A, limit the therapeutic options and increase morbidity and mortality of these patients.
Patricia E. Zerra +15 more
doaj +2 more sources
Comparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19 [PDF]
The Korean Journal of Internal Medicine, 2022 Background/Aims Data comparing the antibody responses of different coronavirus disease 2019 (COVID-19) vaccine platforms according to dose with natural severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection-induced antibody responses are ...
Hye Hee Cha +6 more
doaj +1 more source
Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19 [PDF]
The Korean Journal of Internal Medicine, 2022 Background/Aims The rapidity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific memory B or T cell response in vaccinated individuals is important for our understanding of immunopathogenesis of coronavirus disease 2019 (COVID-19 ...
Ji Yeun Kim +5 more
doaj +1 more source
Anti-SARS-CoV-2 antibody responses in convalescent plasma donors with varying severity of COVID-19 illness [PDF]
Vojnosanitetski Pregled, 2022 Background/Aim. Plasma containing a high titer of anti-SARS-CoV-2 antibodies, donated from individuals who recovered from COVID-19, has the potential to be used as initial therapy for patients who have been infected (passive immunization).
Grujić Jasmina +4 more
doaj +1 more source